Aclaris Therapeutics
ACRS
58 hedge funds and large institutions have $396M invested in Aclaris Therapeutics in 2016 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
40% more capital invested
Capital invested by funds: $284M → $396M (+$113M)
26% more funds holding
Funds holding: 46 → 58 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$9.12M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.88M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$3.71M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.97M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$22.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.77M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$2.58M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$614K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$357K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $56K | +$26.8K | +1,262 | +134% |
|
52
Legal & General Group
London,
United Kingdom
| $42K | – | – | – |
|
53
Canada Life
Winnipeg,
Manitoba, Canada
| $31K | – | – | – |
|
54
Citigroup
New York
| $22K | -$2.69K | -127 | -13% |
|
55
BNP Paribas Financial Markets
Paris,
France
| $17.9K | +$7.42K | +350 | +101% |
|
56
Bank of America
Charlotte,
North Carolina
| $15K | +$9.25K | +436 | +256% |
|
57
BlackRock
New York
| $13K | -$7.4K | -349 | -41% |
|
58
Barclays
London,
United Kingdom
| $4K | +$3.25K | +153 | New |
|
|
TCIM
59
TIAA CREF Investment Management
New York
| $728 | – | – | – |
|
|
TC
60
TFS Capital
West Chester,
Pennsylvania
| – | -$614K | -33,223 | Closed |
|
|
SM
61
Sabby Management
Miami Beach,
Florida
| – | -$292K | -15,812 | Closed |
|
62
Teacher Retirement System of Texas
Austin,
Texas
| – | -$29K | -1,548 | Closed |
|
|
TRCT
63
Tower Research Capital (TRC)
New York
| – | -$2K | -100 | Closed |
|
ACRS Hedge Fund Activity: Q3 2016 in Review
58 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2016, worth a combined $396M — up 40% from $284M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ACRS positions and 4 closed out — a net gain of 12 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $9.12M. The largest seller was RA Capital Management, cutting an estimated $22.9M.
- 58 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2016, up from 46 in Q2 2016.
- Funds reported $396M of Aclaris Therapeutics stock for Q3 2016, up 40% quarter-over-quarter.
- 16 funds opened new Aclaris Therapeutics positions in Q3 2016 and 4 closed out, a net change of +12 holders.
- The largest Aclaris Therapeutics buyer in Q3 2016 was Perceptive Advisors, an estimated $9.12M added.
- The largest Aclaris Therapeutics seller in Q3 2016 was RA Capital Management, an estimated $22.9M sold.
Based on aggregated 13F filings for Q3 2016.